Richard Goodwin

Midatech Pharma (LON:MTPH) Met the CEO & FD at Mello 2019 and conducted post Mello research.First some context. I have no pharma background. Dislike the biotech business model. I'm generally not interested in pre-revenue firms. Risks of Biotech Has a v v small chance of drug passing FDA approvals process, which always takes longer and costs more than anticipated. The approvals process has several stages…

I am keen to move stockbrokers for my ISA and dealing account which is currently with Selftrade (now Equiniti) who have a poor and terribly slow website which doesn't enable trades to be set out of hours and doesn't work with the Chrome browser. I am keen not to go with a small company, nor a bank, nor pay too much! I was considering IG.…

For simplicity I benchmark my portfolios against the FTSE 100. Ideally I would prefer to use an equity only total returns index but have never found a source. I only need access once a month when I update my portfolio spreadsheets to a single value for the index, so it isn't worth paying for. I don't think that the WMA indexes will help as they…

Velocys is a licensor/expert on Gas To Liquids (GTL) technology. It applies this at a small scale to gas to create high value oil related products. It is a university spin out supplemented by some acquisitions and I admire the way they have gone about building alliances, obtaining funding and generally making themselves a very credible proposition in their market (they claim to have a…

I have noticed that amongst the small medtech firms quoted on AIM, a few such as Electrical Geodesics and Lifeline Scentific are US based. I am interested in medtech but slightly wary of overseas companies listed in the UK. Why would US medtech firms chose to list here? If I was comfortable with the answer then I might even invest! Richard

They've been testing it for some time on selected users

Absolutely, Paul is a professional investor, not a professional journalist. To get the quality of commentary for the price you accept (and hopefully enjoy) the quirks!

Presumably Zane either has donors who will be willing to shell out extra to match or the charity has reserves which they are willing to access (bank, property, shares) if it gives overall value accretion.

Thank you immensely @dscollard. You have made me a wiser investor.

I've just dropped a quick email to James Howgego suggesting he look at this thread to better understand PI discontent with HMLH.